Underwriters for the offering included JPMorgan, Bank of America Merrill Lynch, Wells Fargo Securities and Canaccord Genuity. The underwriters were granted a 30-day option to purchase an additional 600,000 shares.
This IPO represents about 13.4% of Penumbra’s outstanding shares and places a market cap on the company of about $895 million, with an outstanding share count of 29.8 million. Gross proceeds of the IPO totaled $120 million, not including the underwriter’s option.
The company said in its Form S-1 filings that it currently has no specific plans for using the net proceeds, but it intends to use the proceeds for product development, including research and development and clinical trials; expansion of the sales force; working capital; and general corporate purposes.
Penumbra’s largest shareholder prior to this IPO was FMR, the investment management division of Fidelity Investments, with a stake of 11.6%, and company directors and executives owned another 24.8%. Neither group sold or bought shares in the IPO, and the two groups now own about 21.7% of outstanding shares. Penumbra said it had a total of 346 shareholders prior to this IPO.
Before noon on Friday, shares traded at $41.40, up 38%. The stock hit a high of $42 earlier in the morning.
ALSO READ: 4 Safe High-Yield Dividend Stocks to Buy for Ongoing Volatility
Top Gaining Stocks
Top Losing Stocks